RE:RE:RE:RE:RE:What's it going to take?Thanks Wordless for the prompt reply. I suppose we could have a discussion on any of these points so let me pick a couple.
Donnatal: CXR doubled the Donnatal sales force and stated that it will take a couple of quarters for the full impact to be realized. Now no one with an expectation of lower sales would invest in 75 or 100 additional sales personnel and expect to lose sales. Considering their market share in that market was only 2% but represents 10% of their NA sales, this should have a positive impact. Script reports do not reflect larger dose per script not does it capture all sales channels as stated by the company. If I was to believe the company or the shorts on this one, I will take the company.
Accounts Receiveable: From the company report in May - " Accounts receivable increased by $43,629. Concordia International accounts receivable increased $11,215 due to increased sales during February and March 2016 when compared to November and December 2015. Concordia North America accounts receivable increased $32,026 as a result of timing of orders within the quarter as well as a change in sales mix during the first quarter of 2016 compared to the fourth quarter of 2015 with a higher proportion of authorized generics revenue which have longer payment terms."
This can also be a result of increased sales momentum heading into Q2. I see it as a positive. The shorts call it fraud. We shall see in a couple of weeks.